CD19 and neoplasm: In both the Nalm6 and K562-CD19Low tumor models, the NKG2D/CD28&CD19 CAR-T cell group demonstrated prolonged survival and greater tumor growth inhibition compared to the traditional CD19 CAR-T cells (Fig. 6B-D).